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Abstract
Stromal cells are connective tissue cells of any organ. Mesenchymal stromal cells (MSCs),
are multipotent progenitors, which were first described by Caplan and colleagues in 1991.
MSCs hold great potential for regenerative medicine because of their ability for self-
renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes,
and adipocytes. Recent studies indicate that MSCs resemble pericytes and emerge from
the peripheral stromal region surrounding blood vessels, thus clarifying their broad
regenerative potential in adult tissues. The development of uniform protocols for both
preparation and characterization of MSCs, including standardized functional assays for
evaluation of their biological potential, are critical factors contributing to their clinical
utility. Nowadays, due to the capacity of modulating immunological responses, suppor-
ting hematopoiesis and repairing tissues, MSCs have been widely used to treat immune-
based disorders, such as Crohn’s disease, rheumatoid arthritis, diabetes, and multiple
sclerosis. Based on animal experiments and clinical studies, the most successful clinical
application of MSCs is in the field of hematological disease.
Keywords: mesenchymal stromal cells, stromal stem cells
1. Introduction
Stem cells have the ability of self-renewal, giving rise to a variety of cell lineages. They const-
itute a significant paradigm of cell-based therapy for various diseases.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Embryonic and non-embryonic stem cells, are the two principal types of stem cells. Embryonic
stem cells (ESCs) originate from the blastocyst’s inner cell mass and have the ability for
differentiation into cells of all three germ layers. However, teratoma formation and ethical
controversy represent an obstacle in their research and clinical application.
On the other side, non-embryonic stem cells, mostly adult stem cells, are fairly specialized and
have limited differentiation potential. They can be isolated from various tissues and are
currently the most used in regenerative medicine.
Over the last decade, cellular therapy has developed quickly at the level of in vitro and in vivo
preclinical research and in clinical trials. Mesenchymal stem cells (MSCs), one type of adult
stem cells, have provided a great amount of interest in the field of regenerative medicine due
to their unique biological properties [1]. The acronym “MSCs” is restricted to the subset of
mesenchymal cells demonstrating stem cell activity by accurate criteria.
1.1. Definition
MSCs are multipotent stromal cells that can differentiate into a variety of cell types, including:
osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes
(fat cells which give rise to marrow adipose tissue). MSCs exist in organisms (in-vivo) and have
been studied as well in tissue culture (in-vitro) [2].
1.2. Terminology
Due to the lack of a particularly unique MSCs function, they have been termed ‘mesenchymal
stem cells’ or interchangeably ‘mesenchymal stromal cells’, ‘BM (bone marrow) stromal cells’
and ‘marrow stromal cells’. MSCs are usually identified by mere plastic adherence and by their
morphological appearance, such as the fibroblastoid phenotype. This procedure leads to a
diverse population containing both single stem cell-like cells and progenitor cells having
various lineage commitment. Compared to hematopoietic stem cells (HSCs), which have been
proven to repopulate the bone marrow and give all blood types, and embryonic stem cells
(ESCs) which after re-injection into early embryos, were proven to participate in embryonic
development of all tissues; MSCs have no established in vivo tests [3].
2. History
In 1970, Friedenstein and colleagues were the first who identified mesenchymal stem cells as
colony-forming unit-fibroblasts (CFU-Fs) [4]. Pittenger and colleagues were the first to desc-
ribe the tri-lineage potential of MSCs [3].
The first clinical trials of MSCs were completed in 1995 when a group of 15 patients were
injected with cultured MSCs to test the safety of the treatment [1].
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3. Sources
3.1. Bone marrow
BM-MSCs are isolated from bone marrow aspirate. This invasive procedure is painful for the
patient with a risk of infection. The commonly used method for the generation of MSCs from
bone marrow is density gradient centrifugation [3]. The collected fraction containing mononu-
clear cells is washed and the cells are seeded on a plastic dish for proliferation.
3.2. Adipose tissue
AT-MSC also termed as adipose-derived stem cells are usually isolated from the biological
material generated during liposuction, lipoplasty or lipectomy procedures by enzymatic diges-
tion with collagenase followed by centrifugation and washing [5].
3.3. Peripheral blood
Following a density gradient centrifugation, PB-MSC can be collected from the mononuclear
cells’ lymphocyte separation fluid fraction. Kassis et al. [6] described another method, which is
loading PB-MSC on fibrin microbeads, then separating the cell loaded beads from the mono-
nuclear fraction. This method allows getting enormous amounts of MSCs [6].
Pittenger et al. [3], isolated MSCs from BM by density gradient centrifugation to eliminate
unwanted cell types and only 0.001 to 0.01% of the cells isolated from the density interface
were identified as mesenchymal stem cells.
3.4. Umbilical cord blood
As umbilical cord blood contains MSCs, it could serve as an alternative source of MSCs to bone
marrow. A novel method to obtain single cell-derived and clonally expanded MSCs that have
multilineage differentiation potential, is negative immunoselection and limiting dilution. The
immunophenotype of these clonally expanded cells is similar with bone marrow mesenchymal
stem cells. These cells can differentiate into bone, cartilage, and fat under suitable induction
conditions. These cells were also able to differentiate into neuroglial- and hepatocyte-like cells;
therefore, these cells may be more than mesenchymal stem cells due to their ability to differ-
entiate into cell types of all 3 germ layers [7].
4. Characteristics
In 2006, the International Society of Cellular Therapy defined characterization of MSCs by the
following three criteria [8]:
1. MSCs must be adherent to plastic under standard tissue culture conditions;
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2. Certain cell surface markers must be expressed such as CD73, CD90, and CD105, other
markers must not be expressed such as CD45, CD34, CD14, or CD11b, CD79 alpha or
CD19 and HLA-DR surface molecules;
3. MSCs must have the capacity to differentiate into osteoblasts, adipocytes, and chondroblasts
under in vitro conditions.
MSCs generally have low immunogenicity as they do not express MHC class II or
costimulatory molecules. Thus, injection of autologous or allogeneic MSCs has been employed
in clinical studies. Allogeneic MSC therapy has the potential to expand MSCs therapy to a
larger range of patients [9].
The effects of MSCs are generally achieved through two mechanisms:
1. Differentiation of recruited MSCs into functional cells to replace damaged cells, permitting
the treatment of organ damage [9].
2. Response of MSCs to inflammatory cytokines, prepares the microenvironment through
production of immune regulatory factors that modulate the progression of inflammation
by affecting dendritic cells, B cells, T cells, and macrophages.
Furthermore, MSCs also produce a large amount of cytokines, chemokines, and GFs, which
stimulate angiogenesis, prevent apoptosis, block oxidation reactions, promote remodeling of
extra cellular matrix, and induce the differentiation of tissue stem cells [10].
In addition, under the effect of signals of cellular damage, known as homing signals, MSCs
migrate toward areas of injury. This migration property of MSCs is important in regenerative
medicine, where various injection routes are utilized depending on the damaged tissue or
organ [11].
5. Morphology
MSCs aredefined bya small cell bodywith a few long and thin cell processes. The nucleus is round
and largewith a prominent nucleolus, in themidst of finely spread chromatin particles, providing
the nucleus a clear appearance. A small amount of rough endoplasmic reticulum, polyribosomes,
Golgi apparatus andmitochondria are also present. The adjacent extracellularmatrix is populated
by a few reticular fibrils however other types of collagen fibrils are absent [12].
6. Differentiation capacity
The identification of specific signaling networks and ‘master’ regulatory genes that control
unique MSCs differentiation lineages represents a major challenge. Obtaining a desired differ-
entiation program, or preventing false differentiation of MSCs, needs ability to modulate
biological effectors for effective clinical application, as in tissue engineering and regeneration.
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6.1. Chondrogenesis
There is similarity between chondrogenic differentiation of MSCs in vitro and of cartilage
development in vivo. In MSC-derived chondrocytes, the following has been positively charac-
terized: expression markers associated with chondrogenesis; including transcription factors
(sox-9, scleraxis) and extracellular matrix (ECM) genes (collagen types II and IX, aggrecan,
biglycan, decorin, and cartilage oligomeric matrix protein) [13, 14]. Many helpful signaling
molecules, involving many transforming growth factor-β (TGF-β), bone morphogenetic pro-
tein (BMP), growth and differentiation factor (GDF) and Wnt ligands, have been recognized
through naturally occurring human mutations and molecular genetic studies. Chondrogenesis
of MSCs from a variety of mesodermal tissue sources is rapidly stimulated by recombinant
proteins and/or adenoviral infection of MSCs with TGF-β1 and TGF-β3, BMP-2, BMP-4, BMP-6,
BMP-12, BMP-13, and GDF-5 [14, 15]. Through specific intracellular Smad proteins and major
mitogen-activated protein kinase (MAPK) cascades, TGF-βs and BMPs signal provide levels of
specificity that are widely studied in MSC differentiation contexts, upon receptor binding [16].
Downstream MAPK signaling and Smad effectors crosstalk has declared that MAPK substrates
include chromatin histone acetyltransferases (HATs). Smads recruit HATs which enhance Smad
transactivation capability [17].
Wnts possess double modulatory function in chondrogenesis. In human MSCs, Wnt7a induces
chondrogenesis through various TGF-β1–MAPK signaling pathways when it is transiently
upregulated, but in case of sustained expression, Wnt7a turns into chondroinhibitory [18].
Wnt3a controls bmp2 expression [19], providing a feed forward regulatory loop during chon-
drogenesis. In ATDC5 cells, chondrogenesis is inhibited by Wnt1 through upregulation of the
mesodermal basic helix–loop–helix (bHLH) transcription factor, Twist 1 [20], this effect may be
through involving negative sequestration of chondrostimulatory factors or direct repression of
target genes.
6.2. Osteogenesis
Two bone morphogenic proteins (BMPs), especially BMP-2 and BMP-6, stimulate osteogenesis
in MSCs. BMP-2 acts by induction the p300-mediated acetylation of Runx2, a master osteo-
genic gene, which leads to enhanced Runx2 transactivating capability. Histone deacetylases 4
and 5 stimulate the degradation of Runx2 by deacetylation, through Smurf1, Smurf2 and E3
ubiquitin ligases [21]. The cytokine TNF-α, involved in inflammation-mediated bone degrada-
tion, downregulates Runx2protein levels by increasing degradation by Smurf1 and Smurf2.
BMPs, Runx2, and histone deacetyltransferases that are responsible for the therapeutic
approaches to MSC-based bone tissue engineering, stimulate existing TNF-α based immuno-
therapy of bone diseases.
Wnts is another important modulator in osteogenesis. Knockout and dosage compensation in
Wnt-pathway-related transgenic animals provide the strongest proof that high levels of endog-
enous Wnts promote osteogenesis, whereas low levels inhibit osteogenesis [22].
The exciting finding of transcriptional mechanisms, suggesting that a global osteogenic gene,
runx2, and a specific osteogenic homeobox gene, tbx5, are responsible for the balance of bone
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formation and loss, show two strong models of transcriptional regulation of osteogenesis, and
potentially other MSC lineage differentiation programs.
6.3. Adipogenesis
MSC adipogenesis is stimulated by the nuclear hormone receptor peroxisome proliferator-
activated receptor γ (PPARγ) but at the same time it represses osteogenesis. Through binding
to various ligands, like long-chain fatty acids and thiazolidinedione compounds, PPARγ
induces the transactivation and transrepression of PPARγ. The bipotent coregulators TAZ
function as a coactivator of Runx2 and as a corepressor of PPARγ, thus promoting osteogen-
esis while blocking adipogenesis [23]. In general, osteogenic genes are corepressed by a
coactivator of adipogenic genes, but the opposite is also possible. This type of cellular effi-
ciency is very likely, allowing that MSCs may be differentiated to both lineages.
Stretch-related mechanoinduction represents another interesting example of exchange
between transcriptional cofactors of adipogenesis. If stretch is induced on mouse embryonic
lung mesenchymal cells they form myocytes but they form adipocytes if uninduced. This
occurs through activation of specific isoforms of tension-induced/inhibited proteins (TIPs)
[24] chromatin-modifying proteins with intrinsic HAT activity that have other distinctive
domains such as nuclear receptor-interacting motifs. TIP-1 which is expressed under non-
stretch conditions provides a potential mechanistic endpoint for cytoplasmic RhoA-mediated
of adipogenesis; induces RhoA signaling which stimulates adipogenesis [25]. Whereas TIP-3
induces myogenesis. These findings propose a molecular model that connects cell morphology
mechanical induction cytoskeletal signaling and transcriptional response during MSC
adipogenesis induction.
6.4. Myogenesis
Themajority of studies ofmyogenesis in adult stem cells target skeletal muscle-derived stem cells,
or satellite cells. The highly successful stimulation of myogenesis from adult stromal MSCs hap-
pened after transfection with activated Notch 1. Other studies, mainly target cardiomyogenesis,
represented the importance of cell-cell contact in stimulating cardiomyogenesis through co-
cultured MSCs and cardiomyocytes, and the stimulation of MSC cardiomyogenesis in a rat
intramyocardial infarct model by Jagged 1, a Notch ligand [26].
In normal conditions, the MSCs are present in low numbers, and on induction of myocardial
infarction (MI) these cells proliferate rapidly to participate in wound healing, by generation of
fibroblasts and myofibroblasts.
After MI, MSCs penetrate the injured tissue by trafficking through the ECM and repairing the
cardiac function. This is through production of HGF by apoptotic cardiomyocytes, and not by
necrotic cardiomyocytes. MSCs are attracted to the apoptotic cell death site by HGF receptor
MET, which are responsible for activation of a wide range of signaling pathways. Platelets
migrate MSCs to the apoptotic cardiac cells by means of the interaction of a nuclear protein
with TLR-4 expressed on MSCs; high mobility group box-1 (HMGB1). On activation of platelet,
HMGB1/TLR-4 downregulate MET on MSCs, thus, decreasing the recruitment of the cells.
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Thereby, gene-knockout or blocking of TLR-4 on MSCs can produce improved infiltration of
MSCs to the damaged tissue, thus, raising the efficacy of MSC-based therapy [27].
In myocardium damage, Stromal cell-derived factor-1α (SDF-1) is a chemokine that mediates
the homing of the endogenous MSCs. An intracellular storage of the receptorCXCR4 present in
80–90% of hMSCs but not expressed in large amounts on the surface. When it is expressed by
mRNA nucleofection, Ca2+ signaling is stimulated through its ligand SDF-1α [28]. However, in
dilated cardiomyopathy (DCM), another homing factor of MSCs, monocyte-chemotactic protein-
1 (MCP-1), has been established because of the presence of chemokine receptor type 2 (CCR2), a
MCP-1 receptor, on the cell surface [29]. Many in-vivo and in-vitro studies have been performed
to comprehend the mechanism of MSC recruitment to the site of the damaged tissue, starting the
process of repair along with its protective role. For the regenerative process to occur, MSCs either
differentiate into beating cardiomyocytes or promote a paracrine effect [30].
7. The immunomodulatory effects of mesenchymal stem cells
Beside cell-to-cell contact, the MSCs secret many factors including EVs and soluble factors
modulating the inflammatory response. The main paracrine factors are TGF-β, prostaglandin E2
(PGE2), hepatocyte growth factor (HGF), IL-10, IL-6, indoleamine 2,3-dioxygenase (IDO), nitric
oxide (NO), and human leukocyte antigen G (HLA-G). Each of these factors plays an important
role in regulation of different target immune cells. Other than such soluble factors, MSCs secrete
extracellular vehicles (EVs), lipid bilayers that contain and transport the cytoplasmic components
of the MSCs. EV is an inclusive term that has recently been suggested to encompass both
exosomes and microvesicles. The immunological potential of MSC EVs in vitro, and the ability
of these EVs to attenuate an activated immune system in vivo have been reported [31].
7.1. Natural killer (NK) cells
MSCs are capable of inhibiting proliferation and function of NK cells, mediated by IDO, PGE2,
and TGF-β1. Many studies have reported that MSCs only partially inhibit the proliferation of
activated NK cells and are susceptible to lysis by activated cells. HLA-G5 inhibits NK cell
mediated cytolysis and decreases interferon-gamma (IFN-γ) secretion [32].
7.2. Dendritic cells (DCs)
Dendritic cells are antigen presenting cells that arise from monocytes or CD34+ hematopoietic
stem cells. After exposure to antigens, they are turned into mature cells. MSCs impair this
differentiation process via PGE2 secretion [33].
7.3. Neutrophils
Chemotaxis attracts neutrophils to the wound site, traversing post capillary venules to lyse
pathogens with the granules within phagolysosomes, and then undergo apoptosis. MSCs secrete
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IL-10 which inhibit neutrophil invasion into the wound. TNF-stimulated gene/protein-6 (TSG-6)
is secreted by MSCs, interacts with protein ligands to inhibit rolling and transendothelial migra-
tion of neutrophils. Dyer [34] found that TSG-6 interacts with the glycosaminoglycan binding
site of CXCL8 (IL-8), a chemokine produced by macrophages and transported to the surface of
the endothelium, impairing neutrophil adhesion and migration.
7.4. Macrophages
Macrophages that arrive at the injury site hours later than neutrophils, are phagocytes that
cleanse the wound of matrix and cell debris. They typically classified into two main groups:
classically activated macrophages (M1) and alternatively activated macrophages (M2). M1 mac-
rophages generally carry antimicrobial characteristics and stimulate a Th1 type response while
M2 macrophages stimulate Th2 type responses. In general, M2 macrophages secrete less
proinflammatory cytokines, have high production of anti-inflammatory cytokines such as IL-10,
and induce resolution of the inflammatory phase. M2b macrophages show the reverse, as they
maintain high levels of inflammatory cytokines [35]. Many studies explain the ability of autolo-
gous or allogeneicMSCs to polarize macrophages toward anM2 phenotype in vitro mediated by
paracrine mechanisms, enhancing expression of M2 associated macrophage genes. Kim and
Hematti [36] have suggested a separate definition for MSC-educated macrophages that secrete
high IL-10 and IL-6 and low IL-12 and TNF-α, to call them M2 m, differing them from other
subcategories. They suggest the possibility of collecting monocytes through leukapheresis and
coculturing these mononuclear cells with allogeneic MSCs to provide MSC-educated macro-
phages prepared for repair of wounds [36].
7.5. B cells
B lymphocytes produce antibodies on exposure for antigens. MSCs may arrest B cell prolifer-
ation in the G0/G1 phase of the cell cycle without enhancing apoptosis [37]. IFN-γ inhibits the
proliferation, which is probably mediated by MSC production of IDO. IDO is the first and rate-
limiting enzyme of the essential amino acid tryptophan catabolism to kynurenine pathway,
producing depletion and therefore halting growth. IFN-γ has IDO inducing effects [38].
7.6. T cells
Inhibitory effects of T cell proliferation by MSCs are mediated by both cell-to-cell contact and
soluble factors. T cell proliferation was suppressed by TGF-β1 and HGF [39]. MSCs secrete
PGE2 which prevents differentiation of CD4+ T cells into Th17 cells. MSCs also release IDO
and enhance secretion of IL-10, which also inhibit cell proliferation [40].
8. Isolation and culturing
All MSCs, despite the protocol used for isolation, characterization and expansion, show the
minimum criteria suggested by International Society for Cellular Therapy.
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hMSCs are isolated based on their adherence ability to plastic surfaces, however, this method
leads to the formation of a diversity of cells (stem cells as well as their progenitor cells) [41].
Considered as the best cell source, Bone marrow-derived MSCs (BM-MSCs) are taken as a
standard to compare MSCs from other sources.
To ensure the success of the usage of these cells as a dependable source for regenerative
medicine, a complete procedure should be established for MSCs isolation, characterization
and expansion [42]. Contrary to bone marrow, MSCs from other tissues can be easily collected
through non-invasive methods and their proliferation could be sustained up to many pas-
sages. Ficoll density gradient method with small modifications is utilized for isolation of MSCs
from bone marrow, peripheral blood and synovial fluid [13] and seeded into culture plates.
During isolation of MSCs from bone marrow, some hematopoietic cells also adhere to the
plastic plate but they are washed away during sub-culturing, leaving only adherent fibroblast
like cells [43]. MSCs from various tissue sources (adipose, dental, endometrium, foreskin,
placenta, Wharton’s Jelly) were isolated after digestion with collagenase and then cultured at
varying densities [42]. Novel marrow filter device is recently explored as an efficient method
for isolation of BM-MSCs [16], avoiding the risk of external contamination and saving time.
Following their isolation from different sources, MSCs were cultured in condition media such
as Dulbecco’s modified Eagle’s media (DMEM), DMEM-F12, DMEM-LG, DMED-HG, αMEM
and RPMI (Roswell Park Memorial Institute medium) [44]. The primary culture medium was
supplemented with fetal calf serum (FCS), new-born calf serum (NBCS) or10% FBS [45].
Besides the culture media and supplementation, the oxygen concentration is very important
in the expansion and proliferation of MSCs [46]. It is also documented when cultured in
DMEM culture with low glucose enriched with growth factors like fibroblast growth factor
(FGF), epidermal growth factor (EGF) and B27 also leads to MSCs expansion [47]. But most
commonly DMEMwith 10% FBS is vastly employed in culturing and expanding MSCs in vitro,
on the other hand, the use of exogenous FBS is highly debated.
8.1. Expression of cell surface markers
One of the essential characteristics of hMSCs is expression of specific set of cell surface
markers. According to the International Society for Cellular Therapy standard criteria, MSCs
are positive for CD73, D90, CD105 but negative for CD14, CD34, CD45 and HLA-DR [8]. MSCs
can be isolated from various human tissues, which express cell surface markers mentioned
above along with positive expression of CD29, CD44, CD146, CD140 b specific to tissue origin.
The expression of CD34, which is a negative marker, is still controversial [48]. Stage-specific
embryonic antigen (SSEA)-4 [49], stromal precursor antigen-1 (Stro-1) and CD146 are reported
as are stemness markers for MSCs [50]. MSCs isolated from the human amniotic fluid express
HLA-ABC [major histocompatibility complex class I (MHC I)], CD29, CD44, CD90, CD105, as
well as SH2 (Src homology 2), SH3 (Src homology 3) and SH4 (Src homology 4). On the other
hand, they lack the expression of HLA-DR (MHC II) [51]. Stro-1, a stemness marker for MSCs,
is reported positive in dental and bone marrow MSCs, while reported negative in human
adipose-derived MSCs (AD-MSCs) [52].
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8.2. Msc niche
Schofield 1978 first introduced a stem cell ‘niche’ term [52]. The niche consists of the elements
surrounding the stem cells in their naïve state including the non-stem cells as well as ECM and
soluble molecules found in that locale. The above factors act together to maintain the stem cells
in their undifferentiated state. Differentiation of the stem cells needs certain signals which
must find their way into the niche for the regeneration or repopulation of a tissue.
8.3. Cellular components
The expression of α-smooth muscle actin (α SMA) in MSCs from all tissue types tested, is the
basis of a perivascular nature of the MSC niche [53] and the immunohistochemical localization
of CD45/CD31/Sca-1+/Thy-1+ cells to perivascular sites [54]. These cells also expressed α
SMA and some even expressed 3G5, a pericyte-associated cell-surface marker. Doherty et al.
[55] suggested that pericytes are in fact MSCs, because their differentiation into osteoblasts,
chondrocytes, and adipocytes. MSCs have easy access to all tissues and participate in healing
of many different tissues due to their presence in perivascular niches throughout the body.
Cadherins, MSCs transmembrane proteins responsible for cell–cell adhesion, polarity, differ-
entiation, migration [18], interact with Wnts, which implicates in the biology of other stem cell
niches [56].
8.4. Soluble components
The nature of bone marrow milieu is hypoxic. Comparison of human MSCs proliferative
capacity was better maintained in the former when cultured in hypoxic versus normoxic
conditions (2 and 20% oxygen). Additionally, hypoxia has doubled the number of existing
CFU-Fs, as well as enhanced the expression of rex-1and oct-4; genes which are expressed by
embryonic stem cells and are crucial in maintaining ‘stemness’. Therefore, through increasing
the plasticity and the proliferative capacity of MSCs, hypoxia is considered to have a double
effect. However, the mechanism of action of hypoxia on MSCs is still unknown, although there
is a possibility through the oct-4 upregulation by the transcription factor hypoxia-induced
factor-2α (HIF-2α) [57].
The effect of proteins secreted in the MSC niche is unexplained. The cell types studied have
either induced differentiation or had no effect on MSCs. Finding soluble proteins permitting
proliferation while inhibiting MSC differentiation would be ideal for simulating the niche and
for MSCs expansion ex vivo.
8.5. Extracellular matrix components
However, ECM alone can regulate MSC differentiation, with potential applications for tissue
engineering, no specific matrix components have been isolated to maintain MSCs in their naïve
state, as a niche matrix would do. For example, osteoblasts on titanium scaffolds leave ECM
after decellularization increasing osteogenesis markers, such as alkaline phosphatase and
calcium deposition, in MSCs [58]. The ability to design artificial matrices that can resemble
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the tissue microenvironment in vivo and control the appropriate differentiation of stem cells is
a promising approach to therapeutic applications. Molecular information on ECM–MSC inter-
actions, involving integrins, which involved in niche biology in other systems [59], is clearly
needed.
9. Applications
9.1. Human mesenchymal stem cells and chronic diseases
MSCs are promising cell source for treatment of autoimmune, degenerative and inflammatory
diseases due to the homing ability, multilineage potential, secretion of anti-inflammatory
molecules and immunoregulatory effects. MSCs role in treating chronic diseases have been
extensively studied in animal disease model.
9.2. Amyotrophic lateral sclerosis
MSCs are capable of differentiating into neurons [60]. An acid sphingomyelinase mouse model
was used to conduct the first MSCs transplantation for neurodegenerative disorders. After
MSCs injection, an amelioration in the overall survivability of the mouse and a decrease in
disease abnormalities were detected [61]. Based on this study, a new study was performed in
order to ensure the MSC transplantation efficiency in a neurodegenerative disease that leads to
motor neurons degeneration and muscle function distortion, Amyotrophic lateral sclerosis
(ALS) [61]. MSCs were isolated from the bone marrow and then reinjected into the spinal cord
of the same patients, followed by MRI at 3 and 6 months for MSCs tracking. Results did not
reveal any abnormal cells proliferation or structural changes in the spinal cord. However, mild
adverse effects occurred which were reversed in few weeks duration e.g. intercostal pain
irradiation and leg sensory dysesthesia. In another study, genetically modified AD-MSCs were
made to express GDNF to be transplanted in a rat model of ALS, an increased number of
neuromuscular connections and an improved pathological phenotype were observed [62].
9.3. Parkinson’s disease
Parkinson’s disease (PD), a neurodegenerative disorder, characterized by significant loss of
dopaminergic neurons. After MSCs transplantation in PD mice model, tyrosine hydroxylase
level increased [63]. MSCs participate to neuroprotection by secretion of trophic factors like
vascular endothelial growth factor (VEGF), EGF, FGF-2, neurotrophin-3 (NT3), HGF and
BDNF without differentiating into neurocytes [64]. Genetically modified hMSCs are used to
induce the secretions of specific factors or to increase the dopamine (DA) cell differentiation.
BM-MSCs transduction with lentivirus carrying LMX1a gene, resulted in cells which were
similar to mesodiencephalic neurons with high DA cell differentiation [65]. Experiments were
performed on Parkinson diseased rat, the research group from the university hospital of
Tubingen in Germany administered BM-MSCs nasally to treat neurodegenerative patients.
MSCs were found in different brain regions after 4.5 months of administration. They have
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been found in the cerebral cortex, olfactory lobe, hippocampus and brain stem, suggesting that
MSCs could successfully survive and proliferate in vivo [66]. Moreover, this type of adminis-
tration was observed to increase the level of tyrosine hydroxylase and decrease the toxin 6-
hydroxydopamine in the ipsilateral striatum and substantia nigra lesions. This novel MSCs
administration route could change the face of MSCs transplantation in future.
9.4. Alzheimer disease
Alzheimer disease (AD), one of the commonest neurodegenerative diseases, characterized by
symptoms as intellectual disabilities, dementia and memory loss. Till present, no treatment
was established to slow down or stop the progression of AD [67]. Researchers use stem cell
therapy in AD animal model aiming to decrease the neuropathological deficits. Mostly by
activating the alternate microglia, increasing the expression of Aβ-degradation enzymes and
decreasing the expression of pro-inflammatory cytokines, that the human AD-MSCs modulate
the inflammatory environment [68]. Furthermore, MSCs modulate the inflammatory environ-
ment of AD and inadequacy of regulatory T-cells (Tregs) and they could modulate microglia
activation [69]. Shin et al. [70] demonstrated that human UCB-MSCs increase the neuronal
survival and stimulate Tregs which control microglia activation in AD mice model. Most
recently, it was confirmed that MSCs stimulates the cell autophagy pathway, causing increased
neuronal survivability and clearing of the amyloid plaque both in vivo and in vitro [70].
9.5. Autoimmune diseases
MSCs have the ability of regulating immune responses, thus it can treat immune disorders.
Other hMSCs can be used for autoimmune diseases treatment, after revealing that human BM-
MSCs are able to protect hematopoietic precursors from inflammatory damage [71].
9.6. Rheumatoid arthritis
Rheumatoid arthritis (RA), a joint inflammatory disease resulting from loss of immunological
self-tolerance. The use of MSCs in animal models’ studies, were successful in slowing disease
progression and enhancing the disease recovery. Beside its anti-inflammatory function, IL-10 is
an important factor in the activation of Tregs that controls self-reactive T-cells and motivates
peripheral tolerance in vivo [72]. Similar effects were produced by human BM-MSCs in the
collagen-induced arthritis model in DBA/1 mice [73]. These studies suggest that the improve-
ment of the RA pathogenesis in DBA/1 mice model in case of using MSCs, can be caused by
activating Treg cells as well as suppressing the production of inflammatory cytokines. How-
ever, MSCs were only effective when administered at the onset of disease, in case of adjuvant-
induced and spontaneous arthritis model, which suggests that MSCs lost their immunoregu-
latory properties when exposed to inflammatory microenvironment [74].
9.7. Type 1 diabetes
Type 1 diabetes, an autoimmune disease caused by the destruction of β-cells due the produc-
tion of auto antibody directed against these cells. As a result, there is decrease in the insulin
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production to a level which is failed to control the blood glucose. It has been proved that MSCs
can differentiate into insulin producing cells and have the capacity to regulate the immuno-
modulatory effects [75]. Zulewski et al. [76] isolated Nestin positive cells from rat pancreatic
islets which differentiated into pancreatic endocrine cells. Nestin positive cells were isolated
from human pancreas and transplanted to diabetic nonobese diabetic/severe combined immu-
nodeficiency (NOD-SCID) mice, which improved hyperglycemic condition [77]. However,
these studies were found controversial and it was suggested that besides pancreatic tissues,
other tissues can be used as an alternative for MSCs isolation to treat type 1 diabetes. Human
BM-MSCs can be differentiated efficiently into pancreatic endocrine cells in vitro as well as
in vivo [78]. There is an option for the use of UCB-MSCs as insulin producing cells. UCB-MSCs
were similar to human ESCs, following similar steps producing the differentiated β-cells [79].
Unsal et al. [80] showed that transplantation ofMSCs together with islets cells into streptozotocin
treated diabetic rat model improve the survival rate of engrafted islets.
9.8. Cardiovascular diseases
Cardiac cells transplantation is a novel strategy for myocardial repair, which is currently applied
in animal models. Although MSCs are a good source for cardiomyocytes differentiation, it was
found that in vitro differentiation is effective only from young cell sources and in vivo differenti-
ation of cardiomyocytes is very rare [81]. MSCs, which have differentiated into cardiomyocytes
under the effect of cocktail of growth factors [82], were used in treatment of left ventricular heart
failure and MI [83]. The systematic injection of BM-MSCs into the infarcted myocardium of
rodent models partially produced recompensation [84]. Katritsis et al. [85] reported improve-
ment in myocardial contractibility when autologous MSCs were transplanted with endothelial
progenitor cells. Despite the fact that MSCs are proven to be effective inMI and related problems,
still the ability of the heart to retain cells is low; only 10% cell retention after 4 h of cells injection
and 1% after 24 h [86]. Roura et al. [87] recorded that UCB-MSCs proliferated and then differen-
tiated into endothelial lineage, were retained for several weeks when injected in acute MI mice.
Transplantation of UCB-MSCs into myocardial infarction animal model along with fibronectin-
immobilized polycaprolactone nanofibers were found very effective [88].
10. Cryopreservation and banking
From all the previous studies, it becomes clear that the use of hMSCs in clinical field will
increase in future. For clinical applications, a large number of MSCs in an ‘off the shelf’ format
is required. For this purpose, cryopreservation and banking are necessary to be established.
This will allow unique opportunities to improve the potential uses of these cells in research
and clinical applications. Keeping in mind its use in future clinical and therapeutic applica-
tions, there is a need to ensure the safety and efficacy of these cells while cryopreserving and
banking. Cryopreservation media should be optimal so uniform change in temperature during
freezing and thawing, long-term storage in liquid nitrogen and employed freezing device are
the main factors to consider.
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In the cryopreservation media in which cells can maintain their stem cells abilities for long
time, the cells require a source of their nutrients as the animal base reagent, like FBS, but
previous studies have showed that there is difficulty in removing animal proteins from the
hMSCs and that may elicit adverse reactions in the patients who receive these cells for treat-
ment [89]. Therefore, a serum-free media is alternative for the cryopreservation of MSCs and it
was successfully used [90]. Lately, instead of using FBS, human albumin and neuropeptide
were used. It was observed that MSCs maintained their proliferation potential and cell sur-
vival in the culture conditions. Moreover, cryoprotective agents (CPAs) are found to be
required for the cryopreservation media to prevent any freezing damage to cells. A large
number of CPAs are available [91], DMSO is the commonest CPAs agent used in cryopreser-
vation of MSCs. However, DMSO toxicity to humans and animals hinders its usage in MSCs
freezing for clinical applications. Due to these complications, it is necessary to use an alternate
CPA. There are many methods along with the introduction of automated cells washing for the
removal of DMSO from the frozen thawed cells [92].
The second important factor in cryopreservation of MSCs is the freezing temperature rate. The
optimum rate for MSCs preservation is slow freezing at the rate of 1C/min is [93]. For the
purpose of maintaining the rate of temperature during cryopreservation, controlled rate
freezers (CRFs) are suitable for regulating the temperature. These CRFs can be programmed
to determine the exact temperature the sample is experiencing during freezing [94]. Despite of
these advantage, these CRFs do not apply a uniform temperature to all vials during large-scale
MSCs banking [95], therefore, the development of advanced CRFs is mandatory for large-scale
banking. Lately, Praxair Inc. created advanced CRF, providing unidirectional flow of cryogen
to each sample. The safe and efficient cryopreservation as well as the regulatory guidelines are
important for large-scale MSCs banking. In the U.S.A., Food and Drug Administration (FDA)
is responsible for supervising MSCs based cell therapy products, while in Europe it is the
European Medicines Agency that is responsible.
11. Summary and conclusion
Mesenchymal stem cells (MSCs) are plastic-adherent, fibroblast-like, multipotent cells found in
the human body having the ability to differentiate into different cell types including osteo-
blasts, adipocytes and chondrocytes. They are normally present in the umbilical cord, adipose
tissue, bone marrow but can also be resident in other tissues and are recruited to sites of
wound healing as well as growing tumors.
MSCs are a promising candidate for cell-based tissue regeneration that can potentially revolu-
tionize the current pharmaceutical landscape. The extracellular matrix (ECM), adjacent cells
and different types of cytokines and growth factors forming MSC niche microenvironment, are
critical for their lineage differentiation. Standardized protocols for cell culture, differentiation,
expansion and cryopreservation need to be in place. These factors in combination with safely
preconditioned and genetically modified MSCs may pave the way for the development of an
effective cellular therapy for countless human immune disorders.
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Recently, research and basic knowledge of these cells has fast-tracked, both from fundamental
and translational perspectives. There have been important discoveries about the available
variety of tissue sources. In addition, novel abilities such as immune-modulation together with
improved delivery to the selected optimal tissue site has been discovered. However, the
molecular fingerprint of MSCs in these contexts remains imprecise and inadequate. Conse-
quently, without this crucial knowledge the progress is difficult in order to determine with
precision the MSCs practical developmental potentials.
Overall, the unavoidable propaganda fluctuation that continued for more than 40 years of
work on BMSCs did not reduce the novel biological flavor of these cells. Concurrently func-
tioning as stem cells and as cells providing the microenvironment for other stem cells, BMSCs
incorporate properties of the “seed” and “soil.” As expectations linked to BMSC plasticity are
diminishing, these unique properties of BMSCs challenge both biology and medicine in a quite
remarkable fashion.
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